Aquestive Therapeutics (AQST) Posts Quarterly Earnings Results

Share on StockTwits

Aquestive Therapeutics (NASDAQ:AQST) announced its earnings results on Thursday. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.35, MarketWatch Earnings reports. The firm had revenue of $16.82 million during the quarter, compared to analyst estimates of $17.05 million. Aquestive Therapeutics updated its FY 2019 guidance to EPS.

NASDAQ:AQST traded up $0.17 on Friday, hitting $6.54. 600 shares of the stock were exchanged, compared to its average volume of 114,662. Aquestive Therapeutics has a 52 week low of $5.60 and a 52 week high of $20.70. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.63 and a quick ratio of 3.42.

Large investors have recently made changes to their positions in the business. New York State Common Retirement Fund acquired a new position in shares of Aquestive Therapeutics during the 4th quarter worth about $28,000. Keybank National Association OH bought a new stake in Aquestive Therapeutics in the third quarter worth approximately $239,000. Bank of New York Mellon Corp bought a new stake in Aquestive Therapeutics in the fourth quarter worth approximately $108,000. Point72 Asset Management L.P. bought a new stake in Aquestive Therapeutics in the third quarter worth approximately $350,000. Finally, Millennium Management LLC bought a new stake in Aquestive Therapeutics in the fourth quarter worth approximately $145,000. 58.34% of the stock is owned by hedge funds and other institutional investors.

AQST has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. Wedbush lifted their price target on Aquestive Therapeutics from $29.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, December 6th. Finally, Lake Street Capital assumed coverage on Aquestive Therapeutics in a report on Thursday, January 3rd. They issued a “buy” rating and a $14.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Aquestive Therapeutics has an average rating of “Buy” and an average target price of $23.60.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4223260/aquestive-therapeutics-aqst-posts-quarterly-earnings-results.html.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

See Also: What is an Initial Public Offering (IPO)?

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Aquestive Therapeutics  Posts Quarterly  Earnings Results
Aquestive Therapeutics Posts Quarterly Earnings Results
TETRA Technologies  Upgraded to Hold at Zacks Investment Research
TETRA Technologies Upgraded to Hold at Zacks Investment Research
Zacks Investment Research Downgrades PPL  to Sell
Zacks Investment Research Downgrades PPL to Sell
Snap  Upgraded to “Buy” by BTIG Research
Snap Upgraded to “Buy” by BTIG Research
Valorbit  Price Tops $0.0001 on Exchanges
Valorbit Price Tops $0.0001 on Exchanges
CoinonatX  Trading Down 1.7% Over Last Week
CoinonatX Trading Down 1.7% Over Last Week


Leave a Reply

© 2006-2019 Ticker Report